An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ALTARGO(Retapamulin) Administered in Korean Patients According to the Prescribing Information.

Trial Profile

An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ALTARGO(Retapamulin) Administered in Korean Patients According to the Prescribing Information.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Retapamulin (Primary)
  • Indications Bacterial skin diseases; Impetigo; Skin and soft tissue infections
  • Focus Adverse reactions
  • Acronyms ALTARGOPMS
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 24 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 13 Mar 2014 Planned number of patients changed from 4500 to 3000 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top